Market Place
Sourcing Support
Arrowhead Emerges as RNAi Knight Amid Sarepta `Downdraft`
12 Aug 2025 //
BIOSPACE
Sanofi pens $395M China pact for Arrowhead Metabolic med
02 Aug 2025 //
PRESS RELEASE
Arrowhead Hits $100M Milestone, Awaits Sarepta Payment
28 Jul 2025 //
FIERCE BIOTECH
Arrowhead Reports Inducement Grants under NASDAQ LR 5635(c)(4)
24 Jul 2025 //
BUSINESSWIRE
Arrowhead Reassures investors about pact with troubled Sarepta
24 Jul 2025 //
PRESS RELEASE
Arrowhead Pharmaceuticals to Webcast Fiscal Q3 2025 Results
21 Jul 2025 //
BUSINESSWIRE
Arrowhead Starts Phase 3 YOSEMITE Study of Zodasiran
08 Jul 2025 //
BUSINESSWIRE
Arrowhead Completes Enrollment in Three Plozasiran Trials
23 Jun 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Begins Study of ARO-ALK7 for Obesity
02 Jun 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals in June 2025 Investor Conferences
29 May 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Q2 2025 Results
12 May 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Join May 2025 Investor Conferences
07 May 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast Q2 Fiscal 2025 Results
30 Apr 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Names Daniel Apel CFO
15 Apr 2025 //
BUSINESSWIRE
Arrowhead Reports Inducement Grants under NASDAQ LR 5635(c)(4)
04 Apr 2025 //
BUSINESSWIRE
Arrowhead Reports Topline Ph1/2 ARO-C3 Data In IgA Nephropathy
10 Mar 2025 //
BUSINESSWIRE
Arrowhead Showcases 2RNAi Candidates For Obesity, Metabolic Disease
06 Mar 2025 //
BUSINESSWIRE
Arrowhead Launches FCS Resources On Rare Disease Day
28 Feb 2025 //
BUSINESSWIRE
Arrowhead`s Preclinical Data On ARO-ALK7 For Obesity Treatment
25 Feb 2025 //
BUSINESSWIRE
Arrowhead & Sarepta Close Global License Agreement
10 Feb 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
10 Feb 2025 //
BUSINESSWIRE
Arrowhead Pharma to Webcast Fiscal 2025 First Quarter Results
22 Jan 2025 //
BUSINESSWIRE
Arrowhead`s NDA For Plozasiran Accepted By FDA For Chylomicronemia
17 Jan 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Starts Phase 1/2a of ARO-INHBE for Obesity
23 Dec 2024 //
BUSINESSWIRE
Arrowhead Reports Inducement Grants under NASDAQ LR 5635(c)(4)
19 Dec 2024 //
BUSINESSWIRE
Arrowhead Presents Interim ARO-CFB Data For Complement Diseases
11 Dec 2024 //
BUSINESSWIRE
Arrowhead Seeks Clearance for ARO-ALK7 in Obesity Study
03 Dec 2024 //
BUSINESSWIRE
Arrowhead to Participate in Upcoming December 2024 Conferences
02 Dec 2024 //
BUSINESSWIRE
Sarepta, Arrowhead ink $1B-plus deal for seven programs
27 Nov 2024 //
FIERCE BIOTECH
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
26 Nov 2024 //
BUSINESSWIRE
Arrowhead Presents New Plozasiran Data at AHA24 & Studies
18 Nov 2024 //
BUSINESSWIRE
Arrowhead Submits NDA for Plozasiran in Familial Chylomicronemia
18 Nov 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
05 Nov 2024 //
BUSINESSWIRE
Arrowhead targets rare disease patients with awareness campaign
05 Nov 2024 //
FIERCE PHARMA
Arrowhead Pharma Reports Inducement Grants under NASDAQ LR 5635(c)(4)
14 Oct 2024 //
BUSINESSWIRE
Arrowhead Files For ARO-INHBE Phase 1/2a Obesity Study
23 Sep 2024 //
BUSINESSWIRE
Arrowhead`s Plozasiran Gets FDA Breakthrough Designation
10 Sep 2024 //
BUSINESSWIRE
Arrowhead Presents Phase 3 Data On Plozasiran For Familial Chylomicronemia
03 Sep 2024 //
BUSINESSWIRE
Arrowhead To Present Plozasiran Phase 3 Data At ESC 2024
21 Aug 2024 //
BUSINESSWIRE
After clearing out heart drug, Arrowhead maps out obesity development plans
15 Aug 2024 //
FIERCE BIOTECH
Arrowhead Pharmaceuticals Announces $500M Financing With Sixth Street
08 Aug 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
08 Aug 2024 //
BUSINESSWIRE
Arrowhead Reports Inducement Grants Under NASDAQ Rule 5635(c)(4)
29 Jul 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
24 Jul 2024 //
BUSINESSWIRE
Arrowhead Axes Heart Disease Drug, Focuses on Another
26 Jun 2024 //
FIERCE BIOTECH
Arrowhead Pharmaceuticals Advances Plozasiran to Phase 3 CAPITAN Trial
25 Jun 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals presents new RNAi-based obesity program data.
24 Jun 2024 //
BUSINESSWIRE
Arrowhead`s Plozasiran Successful Topline Familial Chylomicronemia Data
03 Jun 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
31 May 2024 //
BUSINESSWIRE
Arrowhead Presents Zodasiran Phase 2 Data In Mixed Hyperlipidemia
29 May 2024 //
BUSINESSWIRE
Arrowhead plots next steps for RNAi therapies after mid-stage win
29 May 2024 //
ENDPTS
Arrowhead`s cholesterol drug hits the mark again in ph. 2 trial
28 May 2024 //
FIERCE BIOTECH
Arrowhead: New Phase 2 Plozasiran Data In Mixed Hyperlipidemia Patients
28 May 2024 //
BUSINESSWIRE
Arrowhead Presents ARO-RAGE High Gene Knockdown In Asthma
20 May 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
09 May 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
02 May 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
29 Apr 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
26 Apr 2024 //
BUSINESSWIRE
Arrowhead Initiates ARO-CFB Kidney Disease Study
24 Apr 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
24 Apr 2024 //
BUSINESSWIRE
